A global top 20, Pharma company, involved in developing a set of diagnostic and monitoring tools for Celiac disease, approached Freyr for Investigational New Drug (IND) submissions. Apart from criticality of IND submissions, clients’ strategy for trials in two more regions and requirements of eCTD conversions made the project more challenging.

Read this case study to get insights on how Freyr successfully completed compliant IND submissions in just 4 weeks and met timelines for Phase 1 trials.